Enliven Therapeutics' stock soared 5.35% during intraday trading on Tuesday, driven by a confluence of positive developments for the biotechnology company.

The surge follows the announcement of additional positive Phase 1 clinical trial data for its drug candidate ELVN-001 in chronic myeloid leukemia (CML), which is scheduled for an oral presentation at the upcoming EHA 2026 congress. The updated results show continued meaningful anti-disease activity and a favorable safety profile in a heavily pretreated patient population.

Further bolstering investor sentiment, Guggenheim initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $80. This positive analyst action was highlighted in a broader research roundup. Additionally, the company recently reported quarterly results that beat Wall Street expectations, posting a loss per share of $0.38 compared to the estimated loss of $0.46.